

POSTER PRESENTATION

Open Access

Impact of IgA constant domain on HIV-1 neutralizing function of monoclonal antibody F425-A1g8

X Yu^{1*}, M Duval², C Lewis², L Cavacini¹

From AIDS Vaccine 2012 Boston, MA, USA. 9-12 September 2012

Background

With the majority of HIV infections resulting from mucosal transmission of HIV, induction of an effective mucosal immune response would be pivotal in preventing transmission. HIV-specific IgA but not IgG has been detected in genital tract, seminal fluid, urethral swabs, urine and vaginal wash samples of HIV-negative sex workers and HIV-status discordant couples. Although present at low levels, purified mucosal and plasma IgA from HEPS individuals demonstrated cross-clade neutralizing activity and were able to inhibit HIV mucosal transcytosis.

Methods

The monoclonal antibody F425-A1g8 was generated in our laboratory by hybridoma technique and showed binding activity to the CD4i site of gp120. We isolated the variable genes of heavy chain (VH) and light chain (VL) from the hybridoma cell line and cloned the VH fragment into the vectors pHC-HuC γ 1 and pHC-huC α 1 individually, as well as cloned VL into the vector pLC-huCk. Both of VH and VL plasmids were co-transfected into CHO-K1 cells in equimolar amounts and established F425-A1g8 IgG1 and IgA1 expressing cell lines. We characterized the impact of different isotype variants of F425-A1g8 to HIV neutralizing activity by direct HIV viral neutralizing assay and antibody dependent cell-mediated viral inhibition.

Results

The switching constant domain of F425-A1g8 to construct IgG1 and IgA1 isotypes do not impact their binding activity with the CD4 site binding site of HIV. The result of neutralization showed that in contrast to little

neutralization by F425-A1g8 IgG1 in the absence of sCD4, the IgA1 variant of the antibody displayed significant neutralization activity against a range of HIV clade B isolates.

Conclusion

This research clearly suggests that IgA isotype utilizing its unique molecular structure plays an important role in HIV neutralization. The studies of the neutralizing function of IgA isotypes may also serve to inform the design of vaccine strategies that may be more effective at preventing mucosal transmission.

Author details

¹Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA. ²Beth Israel Deaconess Medical Center, Boston, MA, USA.

Published: 13 September 2012

doi:10.1186/1742-4690-9-S2-P93

Cite this article as: Yu *et al.*: Impact of IgA constant domain on HIV-1 neutralizing function of monoclonal antibody F425-A1g8. *Retrovirology* 2012 9(Suppl 2):P93.

Full list of author information is available at the end of the article



¹Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA